^
Association details:
Biomarker:RAD51 overexpression
Cancer:Ovarian Cancer
Drug Class:Microtubule inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer

Published date:
05/05/2021
Excerpt:
High RAD51 expression indicated unfavorable survival outcomes and resistance to platinum, taxane, and PARP inhibitors in ovarian cancer. In the validation cohort (126 patients), high RAD51 expression indicated platinum resistance, and platinum-resistant patients expressed more RAD51. Patients with high RAD51 expression had shorter OS (HR = 2.968, P < 0.0001) and poorer PFS (HR = 2.838, P < 0.0001). RAD51 expression level was negatively correlated with patients' survival length.
DOI:
https://doi.org/10.1186/s12935-021-01953-5